Minireview: Modulation of hormone receptor signaling by dietary anticancer indoles

Molecular Endocrinology

Volumn 23, Issue 12, 2009, Pages 1940-1947

  Firestone, Gary L ^a   Sundar, Shyam N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRONE; 3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; ESTRADIOL; ESTROGEN RECEPTOR; GAMMA INTERFERON; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOMYCIN C; STEROID RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR SP1;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RESEARCH; CYTOKINE PRODUCTION; HORMONAL REGULATION; HUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; INDOLES; MODELS, BIOLOGICAL; RECEPTORS, GROWTH FACTOR; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 73249152060     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0149     Document Type: Short Survey

References (73)

1. Daniele L, Sapino A 2009 Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies. Recent Pat Anticancer Drug Discov 4:9-18
2. Hynes NE, Macdonald G 2009 ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184
3. Hayes JD, Kelleher MO, Eggleston IM 2008 The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 47 (Suppl 2):73-88
4. Aggarwal BB, Ichikawa H 2005 Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4:1201-1215
5. Kim YS, Milner JA 2005 Targets for indole-3-carbinol in cancer prevention. J Nutr Biochem 16:65-73
6. Weng JR, Tsai CH, Kulp SK, Chen CS 2008 Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262:153-163
7. Bovee TF, Schoonen WG, Hamers AR, Bento MJ, Peijnenburg AA 2008 Screening of synthetic and plant-derived compounds for (anti) estrogenic and (anti)androgenic activities. Anal Bioanal Chem 390:1111-1119
8. Firestone GL, Bjeldanes LF 2003 Indole-3-carbinol and 3-3′-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 133:2448S-2455S
9. Enmark E, Gustafsson JA 1999 Oestrogen receptors-an overview. J Intern Med 246:133-138
10. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS 2002 Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology 143:4172-4177
11. Campbell-Thompson M, Lynch IJ, Bhardwaj B 2001 Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 61:632-640
12. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H 2001 Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537-2541
13. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS 2003 Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27:1502-1512
14. Monroe DG, Johnsen SA, Subramaniam M, Getz BJ, Khosla S, Riggs BL, Spelsberg TC 2003 Mutual antagonism of estrogen receptors α and β and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. J Endocrinol 176: 349-357
15. Sundar SN, Kerekatte V, Equinozio CN, Doan VB, Bjeldanes LF, Firestone GL 2006 Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells. Mol Endocrinol 20:3070-3082
16. Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, Firestone GL 1999 Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59:1244-1251
17. Fan S, Meng Q, Auborn K, Carter T, Rosen EM 2006 BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 94: 407-426
18. Chen D, Carter TH, Auborn KJ 2004 Apoptosis in cervical cancer cells: implications for adjunct anti-estrogen therapy for cervical cancer. Anticancer Res 24:2649-2656
19. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S 1999 Mechanisms of transcriptional activation of bcl-2 gene expression by 17β-estradiol in breast cancer cells. J Biol Chem 274:32099-32107
20. Wang TT, Milner MJ, Milner JA, Kim YS 2006 Estrogen receptor α as a target for indole-3-carbinol. J Nutr Biochem 17:659-664
21. Ashok BT, Chen Y, Liu X, Bradlow HL, Mittelman A, Tiwari RK 2001 Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol. Nutr Cancer 41:180-187
22. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M 2007 Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer. Cancer Res 67:6477-6483
23. Safe S, Wormke M 2003 Inhibitory aryl hydrocarbon receptor-estrogen receptor α cross-talk and mechanisms of action. Chem Res Toxicol 16:807-816
24. Okino ST, Pookot D, Basak S, Dahiya R 2009 Toxic and chemo-preventive ligands preferentially activate distinct aryl hydrocarbon receptor pathways: implications for cancer prevention. Cancer Prev Res 2:251-256
25. Driggers PH, Segars JH, Rubino DM 2001 The proto-oncoprotein Brx activates estrogen receptor β by a p38 mitogen-activated protein kinase pathway. J Biol Chem 276:46792-46797
26. Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R, Safe S 2003 The aryl hydrocarbon receptor mediates degradation of estrogen receptor α through activation of proteasomes. Mol Cell Biol 23:1843-1855
27. Leong H, Firestone GL, Bjeldanes LF 2001 Cytostatic effects of 3,3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-α expression. Carcinogenesis 22:1809-1817
28. Leong H, Riby JE, Firestone GL, Bjeldanes LF 2004 Potent ligand-independent estrogen receptor activation by 3,3′-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol Endocrinol 18: 291-302
29. Riby JE, Chang GH, Firestone GL, Bjeldanes LF 2000 Ligand-independent activation of estrogen receptor function by 3,3′-diindolylmethane in human breast cancer cells. Biochem Pharmacol 60:167-177
30. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y, Kato S 2003 Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423:545-550
31. Mulvey L, Chandrasekaran A, Liu K, Lombardi S, Wang XP, Auborn KJ, Goodwin L 2007 Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Mol Med 13: 69-78
32. Riby JE, Feng C, Chang YC, Schaldach CM, Firestone GL, Bjeldanes LF 2000 The major cyclic trimeric product of indole-3-carbinol is a strong agonist of the estrogen receptor signaling pathway. Biochemistry 39:910-918
33. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
34. Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK, Chang C 1999 Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio J Med 48:87-92
35. Zhang J, Hsu B A JC, Kinseth B A MA, Bjeldanes LF, Firestone GL 2003 Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer 98:2511-2520
36. Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, Firestone GL 2005 Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis 26:1896-1904
37. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF 2003 Plantderived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 278:21136-21145
38. Chinnakannu K, Chen D, Li Y, Wang Z, Dou QP, Reddy GP, Sarkar FH 2009 Cell cycle-dependent effects of 3,3′-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol 219:94-99
39. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, Sarkar FH 2007 Regulation of FOXO3a/β-catenin/GSK-3β signaling by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282:21542-21550
40. Chintharlapalli S, Papineni S, Safe S 2007 1,1-bis(3′- indolyl)-1-(p-substitutedphenyl) methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor γ-independent pathways. Mol Pharmacol 71:558-569
41. Sepkovic DW, Bradlow HL 2009 Estrogen hydroxylation-the good and the bad. Ann NY Acad Sci 1155:57-67
42. Chen I, McDougal A, Wang F, Safe S 1998 Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19:1631-1639
43. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K 2000 Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77
44. Michnovicz JJ, Adlercreutz H, Bradlow HL 1997 Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 89:718-723
45. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF 2004 Pilot study: effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer 50:161-167
46. McAlindon TE, Gulin J, Chen T, Klug T, Lahita R, Nuite M 2001 Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 10:779-783
47. Baud V, Karin M2009 Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40
48. Krikun G, Lockwood CJ 2002 Steroid hormones, endometrial gene regulation and the Sp1 family of proteins. J Soc Gynecol Investig 9:329-334
49. Deniaud E, Baguet J, Mathieu AL, Pagès G, Marvel J, Leverrier Y 2006 Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 25:7096-7105
50. Tan NY, Khachigian LM 2009 Sp1 Phosphorylation and its regulation of gene transcription. Mol Cell Biol 29:2483-2488
51. Cram EJ, Liu BD, Bjeldanes LF, Firestone GL 2001 Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem 276:22332-22340
52. Hong C, Kim HA, Firestone GL, Bjeldanes LF 2002 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 23:1297-1305
53. Hung WC, Chang HC 2009 Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells. J Agric Food Chem 57:76-82
54. Chinni SR, Sarkar FH 2002 Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8:1228-1236
55. Safe S, Kim K, Kim K2008 Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41:263-275
56. Chang X, Firestone GL, Bjeldanes LF 2006 Inhibition of growth factor-induced Ras signaling in vascular endothelial cells and angiogenesis by 3,3′-diindolylmethane. Carcinogenesis 27:541-550
57. Kim HS, Lim IK 2009 Phosphorylated extracellular signal-regulated protein kinases 1 and 2 phosphorylate Sp1 on serine59 and regulates cellular senescence via transcription of p21Sdi1/Cip1/Waf1. J Biol Chem 284:15475-15486
58. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC 2005 The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12 (Suppl 1):S37-S46
59. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ 2008 The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68:6762-6769
60. Kalaitzidis D, Gilmore TD 2005 Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol Metab 16: 46-52
61. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF 2008 The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8:187-198
62. Renner O, Blanco-Aparicio C, Carnero A 2008 Genetic modelling of the PTEN/AKT pathway in cancer research. Clin Transl Oncol 10:618-627
63. Moiseeva EP, Heukers R, Manson MM 2007 EGFR and Src are involved in indole-3-carbinol-induced death and cell cycle arrest of human breast cancer cells. Carcinogenesis 28:435-445
64. Rahman KW, Sarkar FH 2005 Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65:364-371
65. Moiseeva EP, Almeida GM, Jones GD, Manson MM 2007 Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 6:3071-3079
66. McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S 2006 3,3′-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res 132:208-213
67. Xue L, Firestone GL, Bjeldanes LF 2005 DIM stimulates IFNγ gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24:2343-2353
68. Chang X, Tou JC, Hong C, Kim HA, Riby JE, Firestone GL, Bjeldanes LF 2005 3,3′-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 26:771-778
69. Kunimasa K, Kobayashi T, Sugiyama S, Kaji K, Ohta T 2008 Indole-3-carbinol suppresses tumor-induced angiogenesis by inhibiting tube formation and inducing apoptosis. Biosci Biotechnol Biochem 72:2243-2246
70. Chatterji U, Riby JE, Taniguchi T, Bjeldanes EL, Bjeldanes LF, Firestone GL 2004 Indole-3-carbinol stimulates transcription of the interferon γ receptor 1 gene and augments interferon responsiveness in human breast cancer cells. Carcinogenesis 25:1119-1128
71. Riby JE, Xue L, Chatterji U, Bjeldanes EL, Firestone GL, Bjeldanes LF 2006 Activation and potentiation of interferon-γ signaling by 3,3′-diindolylmethane in MCF-7 breast cancer cells. Mol Pharmacol 69:430-439
72. Xue L, Pestka JJ, Li M, Firestone GL, Bjeldanes LF 2008 3,3′-Diindolylmethane stimulates murine immune function in vitro and in vivo. J Nutr Biochem 19:336-344
73. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL 2008 The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci USA 105:19750-19755